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Leiomyosarcoma is a rare malignancy with a poor prognosis. It is however one of the commonest
pulmonary artery sarcomas and arises from pleuripotent cells found in the intima of the vessel. Its
presentation often mimics other conditions such as pulmonary embolism causing a delay in diagnosis.
This article describes a unique case of leiomyosarcoma of the pulmonary artery presenting as progressive
cavitating lung disease with multi-level vertebral deposits. A presumptive diagnosis of tuberculosis had
previously been made with apparent improvement following treatment. However, despite extensive
investigation, attempts to secure a tissue diagnosis were unsuccessful and this was made only after post-
mortem examination.
 2009 Elsevier Ltd. All rights reserved.1. Case report
A 66-year-old retired lorry driver was investigated by chest
physicians because of a left upper lobe cavitating lesion and back
pain. His history was remarkable for a left lower lobectomy aged 18
for bronchiectasis, thought secondary to TB, fromwhich his mother
had died. He was an independent ex-smoker of forty pack years
with no travel history outside the UK. Bronchoscopy to investigate
his cavitating lesion was unremarkable, with samples being nega-
tive for bacterial culture and acid-fast bacilli. He was treated
empirically with rifampicin, isoniazid and pyrazinamide with
radiological improvement at six months.
One year later he re-presented with weight loss, night sweats,
haemoptysis and back pain. A CT scan revealed a new right upper
lobe cavity and scarring in the left upper lobe. An MRI scan was
reported as showing lesions compatible with TB at L2 and S2.
Sputum smears and serum ANCA were negative, bronchoscopic
washings were negative for TB on direct smear and culture and
conventional antibiotics were unhelpful. He was treated as reac-
tivated TB with rifampicin, isoniazid, pyrazinamide, ethambutol
and moxiﬂoxacin. Clinical and radiographic improvement was seen
again after one month in keeping with the presumptive diagnosis.
After two months of treatment he presented to a second
hospital with a collapse and a two-week history of worsening backx: þ44 117 9596073.
h).pain, dyspnoea and haemoptysis. CXR showed cavitating lesions in
both upper zones. MRI showed persisting and new lytic lesions in
several vertebral bodies most marked at L2 (Fig. 1). CT guided and
subsequent open biopsies of L2 were undertaken but were non-
diagnostic. There was no growth on either standard or TB culture
and TB PCR was negative. Despite this anti-tuberculous chemo-
therapy was continued.
He re-presented after ﬁve months of treatment with fevers and
worsening back pain. MRI revealed new spinal lesions. CT now
showed multiple cavitating lung lesions (Fig. 2). Bronchoscopy,
trans-bronchial biopsies and bronchoalveolar lavage were unre-
markable, all laboratory tests for TB were negative. Repeat open
vertebral biopsies demonstrated non-speciﬁc inﬂammation, bone
culture and mantoux testing were negative. In the absence of
clinical improvement or positive microbiology all anti-tuberculous
medications were stopped, after a total of six months.
Reassessment that week revealed a new systolic murmur and
echocardiography demonstrated severe pulmonary hypertension.
A CT pulmonary angiogram (CTPA) was negative for pulmonary
embolus but the left upper lobe artery now appeared narrowed.
There was a suggestion of abnormal soft tissue at the left hilum
with progression of bony lesions and pulmonary cavities.
A trial of systemic steroids was initiated with improvement in
pain and mobility permitting transfer to a spinal unit at a third
hospital for stabilisation of L2.
At the spinal unit he developed left sided pleuritic chest pain.
A CTPA showed that several of the pulmonary cavities were asso-
ciated with thrombosed pulmonary vessels and that the left
Fig. 1. T1 weighted sagittal MRI of the spine demonstrating multi-level disease. With
permission from Weston General Hospital, UK.
Fig. 3. CTPA demonstrating occlusion of the left pulmonary artery. With permission
from North Bristol NHS Trust, UK.
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enhanced MRI implied that this was due to thrombus rather than
tumour. Additionally there were destructive bone lesions at
multiple new sites (Fig. 4). Within days he succumbed to over-
whelming respiratory sepsis, four years afterhis initial presentation.
Post-mortem examination conﬁrmed the left pulmonary artery
to be occluded by old thrombus. There was dense ﬁbrotic tissue
involving the left pulmonary artery and evidence of cavitating
infarction in both upper lobes with multifocal disease in the
vertebral column. The right lung showed widespread pneumonic
change of recent onset.
Histology from the left hilum and bony lesions was identical
showing a spindle cell neoplastic lesionwith a prominent storiform
pattern. Immunohistochemical staining was positive for vimentin
and smooth muscle actin and negative for cytokeratins, macro-
phage markers, CD99 and CD34. A diagnosis of pulmonary artery
leiomyosarcoma (PA-LMS) with spinal metastases was made.Fig. 2. CT chest demonstrating cavitating lesions and loss of volume on the left. With
permission from Weston General Hospital, UK.2. Discussion
Leiomyosarcoma (LMS) is from a histologically diverse group of
pulmonary artery sarcomas (PAS). It remains notoriously difﬁcult to
diagnose and although rare is the commonest primary pulmonary
artery malignancy. Here we will discuss the condition with an
emphasis on features which may hasten its diagnosis.
First described in 1923 by Mandelstramm, pulmonary artery
sarcomas are thought to arise from pleuripotent cells found in the
intima of the vessel. Because of its mesenchymal origins LMS is
reported as arising within tissues as disparate as the testis1 and
tongue2 which along with its propensity to cause systemic features,
explains why it may be regarded as a great mimic.
The aetiology of leiomyosarcomas remains unclear. However
malignant ﬁbrous histiocytoma (MFH, one of the pulmonary artery
sarcomas) is known to occur in areas of chronic inﬂammation such
as gouty tophi3 at the site of internal ﬁxation of fractures4 and at the
site of chronic infection.5,6 Takanami et al. report a latent period of
sixteen years between pleuropneumonectomy and the diagnosis ofFig. 4. T1 weighted sagittal MRI of the spine demonstrating progression of disease and
collapse of L2. With permission from North Bristol NHS Trust, UK.
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thoracic surgery in the form of a left lower lobectomy, the same side
as he later developed PAS.
An infective aetiology has also been postulated with a case of
PA-LMS reported with the tumour itself expressing the Epstein Barr
virus some years after symptomatic EBV infection in an immuno-
competent individual.8
PAS usually affect adults within the age range of 45–64. Symp-
toms are largely related to the pathophysiology of the tumour
which causes increasing disruption to the right ventricular outﬂow
tract (RVOT). Patients most often present with exertional dyspnoea,
but chest pain, cough, weight loss and haemoptysis are also seen.11
Syncope suggests signiﬁcant compromise of the RVOT; chest pain
and haemoptysis may be due to metastatic emboli (seen in
approximately two thirds of cases9) or local invasion into an airway.
Around half of PAS cases show transmural spread into the
surrounding lung parenchyma, airways or lymph nodes.9 Tumour
embolism may cause pulmonary infarction and result in fever and
later cavitating disease. Presentation may not occur until there is
signiﬁcant occlusion of the pulmonary vasculature.10
Systemic metastases are found in 20%9 of cases and have
previously been described at sites including the liver, pancreas,
mesentery, brain, adrenals, kidneys, thyroid and the skin.11 To our
knowledge our case of PA-LMSmetastasising to the spine is unique.
Bony deposits with PA-LMS are rare, our search revealed only two
cases in the English literature, one involving the hip12 with the
other site being unspeciﬁed.13
Laboratory ﬁndings are seldom helpful. Patients often have
markers of systemic upset generally not seen in pulmonary
embolus, with which they are erroneously diagnosed in more than
half of cases.9 Laboratory features of chronic inﬂammation impli-
cate a myriad of other conditions. There have however been case
reports of leiomyosarcoma where these have been prominent and
have resolved after excision of the tumour14 in keeping with
a paraneoplastic phenomenon. The possible secretion of adrena-
line-like substances from a PAS has also been reported with the
patient presenting as if with phaeochromocytoma.15
Other reported misdiagnoses are pulmonary artery stenosis,
extrinsic compression by bronchial tumour or mediastinal mass.9,11
The clinical presentation of PA-LMS may be indistinguishable
from that of pulmonary TB. Both conditions can incite a systemic
inﬂammatory response with cavitating lung disease, which in the
case of PA-LMS is due to pulmonary infarction. This dilemma has
previously been reported with the patient being treated for TB on
the basis of clinical suspicion alone.16 In our case the known
exposure to TB and apparent improvement on anti-tuberculous
treatment fuelled the pursuit of this diagnosis.
Chest x-rays may be normal or may show a hilar mass, pulmo-
nary nodules or inﬁltrates, cardiomegaly, PA prominence, pleural
effusion or oligaemic lung ﬁelds.
ECG may demonstrate right ventricular strain. Similarly echo-
cardiogram may reveal elevated PA pressures and in some cases
may delineate the tumour itself. Trans-oesophageal echo offers
superior images of the pulmonary trunk and artery and so gives
a greater chance of visualising the tumour.
As discussed PAS may be difﬁcult to differentiate from the more
frequently encounteredPE. Distinguishing between these diagnoses
is challenging; bothmay embolise distally or indeed co-exist where
a vessel is narrowed by LMS. CT scanning is helpful in so far as itmay
show local invasion of the tumour or its metastases.13 However it
cannot discriminate between tumour and thrombus in the PA. MRI
with gallium based contrast media to achieve this was described as
early as 1976.17 Tumour within the PA enhances with this tech-
nique.10,18 Additionally tumour (but not thrombus) shows uptake on
FDG-PET scanning.9 Angiography may show an intraluminallobulated tumour which when pedunculated has been described as
having a ‘‘to-and-fro’’movementwith each cardiac contraction.9,11,18
Ventilation-perfusion scanning offers little to allow differentia-
tion between tumour and embolus. It is noteworthy however that
perfusiondeﬁcits secondary to PASwill remain unchangedover time
despite adequate anticoagulation11–13 and that large unilateral
perfusion defects are uncommon in PE.19 Failure to improve despite
adequate anticoagulation,withnoclear risks forVTEandnoevidence
of DVT should raise the possibility of an alternative diagnosis.
Although surgery offers the only known means of cure, many
cases are found intra-operatively to be unresectable. A high index of
suspicion and a careful search for metastases may prevent inap-
propriate procedures and allow palliation. Potential surgical inter-
ventions include pneumonectomy, pulmonary endarterectomy and
resection with PA reconstruction. Kaplan–Meier survival curves
suggest a mean survival of 1.5 months after diagnosis, Parish et al.
report a series with one case surviving 3.5 years after diagnosis.11
Surgical intervention (largely to ameliorate haemodynamic
compromise) extends the median survival to 10 months.13 Death is
usually related to RVOT compromise and RV dysfunction.
The role of chemotherapy remains unclear. Diagnosis is usually
too late for it to be effective, and the rarity of the condition makes
its evaluation far from straight forward.
Our unique case illustrates the diagnostic difﬁculties associated
with pulmonary artery sarcomas as well as the way its presentation
can overlap with that of pulmonary TB.
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